Open-label Extension Study Evaluating the Safety and Efficacy of Long-term Use of Relacorilant in Patients With Endogenous Hypercortisolism (Cushing Syndrome): Interim Analysis Results
Summary
- Relacorilant is a selective glucocorticoid receptor modulator in development for the treatment of endogenous hypercortisolism (Cushing syndrome [CS]) of all etiologies
- The presented ongoing open-label phase 2/3 extension study investigates the long term safety and efficacy of relacorilant treatment in patients with endogenous CS
- This interim analysis provides support for the long-term tolerability and efficacy of relacorilant in patients with endogenous CS
- Relacorilant led to improvement and/or long-term maintenance of clinical and cardiometabolic benefit